S-palmitoylation of the v-ATPase subunit RNAseK is necessary for Zika virus infection Authors: Santiago Leiva, Patricia Recordon-Pinson, Lucile Fischer, Marie-Line Andreola, Emmanuelle Thinon Published: 2026 ABSTRACT AbstractBackgroundS-palmitoylation is a reversible and dynamic lipid post-translational modification that regulates protein localisation, stability, and function. During viral infections, S-palmitoylation can modulate viral replication by directly modifying viral proteins or by altering host proteins involved in the viral life cycle and immune responses. In this study, we investigated the role of S-palmitoylation of Ribonuclease Kappa (RNAseK) during infection with Zika virus (ZIKV), a member of the flavivirus family. RNAseK is an 11 kDa transmembrane protein recently identified as a component of the vacuolar ATPase complex and required for efficient infection by flaviviruses.MethodsWe used site-directed mutagenesis, metabolic labelling with alkyne-tagged palmitate, and the Acyl-PEG Exchange (APE) assay to identify S-palmitoylation sites on RNAseK. A549 cells stably expressing wild-type or S-palmitoylation-deficient RNAseK mutants were infected with ZIKV. Viral replication was assessed by flow cytometry, RT-qPCR, and TCID₅₀ assays. Immunofluorescence was used to evaluate the role of S-palmitoylation in protein localisation. Cycloheximide chase and proteasome inhibition assays were used to assess protein stability, while lysosomal acidification assays were used to assess lysosomal pH changes.ResultsRNAseK was found to be S-palmitoylated on four cysteine residues (Cys6, Cys7, Cys14, and Cys85). Substitution of these residues with alanine abolished protein S-palmitoylation. Cells stably expressing the S-palmitoylation-deficient RNAseK mutant exhibited decreased ZIKV replication and reduced production of infectious viral particles compared to wild-type RNAseK-expressing cells. S-palmitoylation was required for RNAseK stability and reduced its proteasomal degradation, but did not affect its cellular localisation. S-palmitoylation of RNAseK also contributed to lysosomal acidification, a process important for ZIKV infection.ConclusionsThis study identifies RNAseK S-palmitoylation as a determinant of protein stability and efficient ZIKV infection in human cells. More broadly, it highlights the importance of lipid post-translational modifications in host-pathogen interactions and suggests that targeting RNAseK S-palmitoylation may represent a potential antiviral strategy against ZIKV. Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12985-026-03216-z.Keywords: S-palmitoylation, S-acylation, Zika virus, Flavivirus, Host protein, v-ATPase Introduction S-palmitoylation is a post-translational lipid modification of proteins that involves the covalent attachment of a fatty acid, mainly the 16-carbon saturated fatty acid known as palmitic acid, to cysteine residues via a thioester bond [1–3]. Unlike other lipid modifications such as myristoylation or prenylation, S-palmitoylation is reversible and dynamically regulated by two types of cellular enzymes: palmitoyl acyltransferases (e.g., ZDHHC family) and acyl-protein thioesterases. This enables cells to regulate this modification in a temporally and spatially precise manner. Notably, this post-translational modification can regulate several aspects of protein function, including subcellular localisation, stability, membrane association, protein-protein interactions, and trafficking [1–3]. In the context of viral infections, S-palmitoylation has emerged as an important regulatory mechanism for both viral and host proteins that participate in different stages of the viral life cycle. For instance, in Chikungunya virus (CHIKV), the nonstructural protein 1 (nsP1) undergoes three S-palmitoylation events. These modifications are required for proper nsP1 localisation and are crucial for the formation of the viral replication complex [4]. The hemagglutinin (HA) protein of influenza A virus is S-palmitoylated at multiple conserved cysteine residues, which modulates its incorporation into lipid rafts, promotes membrane fusion, and is essential for efficient viral budding and infectivity [5]. The nonstructural protein 2 (NS2) of hepatitis C virus (HCV) is S-palmitoylated at Cys113. This modification is required for its correct subcellular localisation to endoplasmic reticulum-derived membranes and for efficient autocatalytic cleavage, both of which are critical for HCV replication and assembly [6]. Similarly, some host antiviral proteins, such as interferon-induced transmembrane proteins (IFITMs), also require S-palmitoylation for optimal function [7, 8]. S-palmitoylation of IFITM3 at Cys72 regulates its membrane localisation and antiviral activity against a wide spectrum of RNA viruses, such as Zika virus (ZIKV), Dengue virus or Influenza A virus [9]. Together, these examples highlight how S-palmitoylation can modulate the life cycle of RNA viruses by directly modifying viral proteins or by altering host proteins involved in the viral life cycle and immune mechanisms. In our study, we assess the role of S-palmitoylation of Ribonuclease Kappa (RNAseK). This relatively understudied small transmembrane protein has recently gained attention for its role in viral infection, particularly among members of the Flaviviridae family [10–12]. Recent evidence suggests that RNAseK is a component of the vacuolar ATPase (v-ATPase) complex [13]. The v-ATPase complex plays a key role in endosomal acidification [14], which is essential for the uncoating and fusion of many enveloped viruses, including flaviviruses. Acidic pH within endosomes triggers conformational changes in the E glycoprotein of flaviviruses, allowing for membrane fusion and genome release into the cytoplasm [15]. Moreover, endosomal acidification is also required during the final step of virion maturation, in which the acidic pH facilitates the cleavage of the membrane protein precursor (prM), leading to the formation of fully mature and infectious viral particles [16]. The use of chemical compounds that inhibit endosomal acidification mediated by the v-ATPase complex, such as Bafilomycin A1, has been shown to be a potent inhibitor of flavivirus replication in cell culture [17]. Importantly, v-ATPase function is not only critical for viral entry but also for intracellular trafficking, autophagy, and immune signalling, all processes potentially hijacked by flaviviruses [13]. Recent studies have demonstrated that RNAseK depletion impairs flavivirus infection in cell culture models. While several reports found no significant alterations in endo-lysosomal acidification [10–12], other data suggest that RNAseK depletion may affect endo-lysosomal pH [18]. Consequently, the precise mechanism by which RNAseK contributes to flavivirus infection remains unclear. Interestingly, S-palmitoylation of the V0a1 protein, a subunit of the V0 domain of the v-ATPase complex, is essential for its membrane localisation and function in acidification [19], suggesting that this lipid modification may play a broader role in regulating the activity of the entire complex. In this context, in a previous mass spectrometry-based proteomic analysis, RNAseK was identified as a candidate S-palmitoylated protein [20]. Given the well-established role of S-palmitoylation in regulating protein localisation, stability, and interaction with membrane compartments, this post-translational modification may be of particular relevance for RNAseK function, especially considering its reported function as a subunit of the v-ATPase complex [13]. We designed a combination of site-directed mutagenesis, biochemical assays, and virological approaches to characterize the S-palmitoylation sites on RNAseK and examined how these modifications affect protein stability and viral infection. Altogether, this study provides insight into the functional importance of RNAseK lipidation in flavivirus infection and highlights S-palmitoylation as a potential regulatory node in virus-host interactions. Materials and methods Plasmids The pcDNA-RNAseK-FLAG-WT plasmid was generated using synthetic DNA encoding the reference mRNA sequence of the RNAseK gene (Accession number: NM_001004333.4), cloned into a mammalian expression vector (pcDNA 3.1(+)-FLAG) under the control of the CMV promoter, enabling expression of the RNAseK protein tagged with a FLAG epitope. This plasmid served as the template for the generation of additional RNAseK variants using the Q5 Site-Directed Mutagenesis Kit (Promega), following the manufacturer’s instructions. Specific mutations were introduced using the corresponding sets of primers. For introduction of the mutation C6A, we used 5’-GTC GCT CCT GGC CTG TGG GCC GA-3’ (sense) and 5’-GCC ATA AAG AAG GGA GTC G-3’ (antisense). For introduction of the mutation C7A, we used 5’-GCT CCT GTG CGC TGG GCC GAA GC-3’ (sense) and 5’-GAC GCC ATA AAG AAG GGA G-3’ (antisense). For introduction of the mutation C14A, we used 5’-GCT GGC CGC CGC CGG CAT CGT CC-3’ (sense) and 5’-TTC GGC CCA CAG CAC AGG-3’ (antisense). For introduction of the mutation C69A, we used 5’-CAG CTA CAA CGC TTT CAT CGC TGC AG-3’ (sense) and 5’-ACT TGC TCG TAA AGG TTG-3’ (antisense). For introduction of the mutation C85A, we used 5’-CTT CTC TTT CGC CCA AGT TCG GCT CAA TAA G-3’ (sense) and 5’-CCT CCG AGG AGG AGG TAA-3’ (antisense). For generation of the shRNAseK-resistant constructs: 5’-AAT CTG TAT GAG CAA GTC AGC TAC-3’ (sense) and 5’-ATA GAT ATT CTG GGG GCC ATT C-3’ (antisense). Additionally, synthetic DNA encoding a small hairpin RNA (shRNA) targeting human RNAseK (shRNAseK) was cloned into the pLKO.1-Puro lentiviral transfer vector under the control of the U6 promoter. The sequence for shRNAseK was previously described and validated [11]. The plasmid mApple-LAMP1‐phLuorin‐N‐8 was kindly provided by Dr. Volker Gerke (University of Münster, Germany). Visualisation of MS/MS spectra of RNAseK MS/MS spectra of modified peptides were opened in MaxQuant version 1.5.0.25 using the analysis performed by Thinon et al. [20]. Alk-16 metabolic labelling and IP/Click HEK293T cells were seeded in a 6-well plate 24 h prior to the experiment to reach approximately 80% confluence. Then, cells were transfected with RNAseK-FLAG constructs using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. 24 h post-transfection, the culture medium was replaced with growth medium supplemented with alk-16 (final concentration: 50 µM), prepared as previously described [21]. After an additional 24 h, cells were harvested, washed twice with ice-cold PBS, flash-frozen, and stored at − 80°C. For lysis, frozen cell pellets were resuspended in lysis buffer containing 1% Brij 97, 150 mM NaCl, 50 mM HEPES (pH 7.4) and EDTA-free protease inhibitor cocktail (Roche). Lysates were incubated on ice for 15 min and clarified by centrifugation at 500 × g for 10 min at 4 °C to remove cellular debris. FLAG-tagged proteins were immunoprecipitated using anti-FLAG magnetic beads (Pierce, A36797) by incubating for 1 h at 4 °C with end-over-end rotation. Beads were then washed three times with 1 mL of ice-cold IP wash buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM HEPES, pH 7.4). The beads were resuspended in 20 µL of 0.25% SDS in 50 mM HEPES 150 mM NaCl pH 7.3 and 5 µL of click mixture [azido-rhodamine (0.5 µL, 10 mM stock solution in DMSO, final concentration 0.2 mM), CuSO4 (1 µL, 50 mM in H2O, final concentration 2 mM), TCEP (1 µL, 50 mM in H2O, final concentration 2 mM), TBTA (0.5 µL, 10 mM stock solution in DMSO, final concentration 0.2 mM)] were added. Beads were incubated at room temperature for 1 h and EDTA (1 µL of a 0.5 M solution in H2O) was added to stop the CuAAC reaction. Beads were washed 3 × 5 min with “IP wash buffer”. Proteins were eluted by boiling the beads for 5 min in 1X Laemmli sample buffer (BioRad) and separated by SDS-PAGE. The gel was washed twice with deionised water before in-gel fluorescence detection using an Amersham ImageQuant imager (Cytiva). The gel was then transferred to a 0.2 μm nitrocellulose membrane (Cytiva) using a Trans-Blot Turbo Transfer System (Bio-Rad) (30 min, 25 V constant). The membrane was blocked with 5% milk in TBS-T (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature, incubated with anti-FLAG (F7425, Sigma, 1/1000 in 5% milk in TBS-T), washed 4x TBS-T and incubated with HRP-anti-Rabbit (111-035-003, JacksonImmuno Research, 1/5000 in 5% milk in TBS-T). The membrane was washed with TBS-T. Protein detection was performed with ECL detection reagent (GE healthcare) on an Amersham ImageQuant imager (Cytiva). Acyl-PEG exchange (APE) The APE protocol was performed as previously described [22]. HEK293T cells were seeded in a 6-well plate 24 h prior to the experiment to reach approximately 80% confluence. Then, cells were transfected with RNAseK-FLAG constructs using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. After 24 h post-transfection, cells were harvested, washed twice with ice-cold PBS, flash-frozen, and stored at − 80°C. For lysis, frozen cells were resuspended in 4% SDS, 150 mM NaCl, 50 mM triethanolamine (TEA) pH 7.4, 1 mM EDTA, benzonase, EDTA-free protease inhibitor (Roche). Lysates (200 µg) were diluted with 150 mM NaCl, 50 mM TEA pH 7.4 to 92.5 µL. 5 µL of 200 mM neutralised TCEP (Thermo, final concentration of 10 mM TCEP) were added and incubated at room temperature for 30 min with end-over-end rotation. 2.5 µL N-ethylmaleimide (1 M stock in ethanol, freshly prepared, 25 mM final concentration) were added and the solution was incubated for 2 h at room temperature. Proteins were precipitated by CHCl3/MeOH precipitation. The protein pellets were allowed to air-dry for 5–10 min, resuspended in 92.5 µL of 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA. The reduction/alkylation was repeated and proteins were precipitated with CHCl3/MeOH (2x). Proteins were resuspended in 50 µL 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA. Samples were split into two 25 µL aliquots - or + NH2OH (100 µg/condition). For the NH2OH-treated sample, 75 µL NH2OH 1 M, 0.2% Triton X-100, pH 7.4 in H2O was added to the “+NH2OH” sample for a final concentration of 0.75 M NH2OH, 1% SDS (Lysate: NH2OH solution 1:3). For the negative control not treated with NH2OH, 75 µL 50 mM TEA, 0.2% Triton X-100, 150 mM NaCl pH 7.4 was added to the samples (“NH2OH”) for a final concentration of 1% SDS (Lysate: Buffer 1:3). After 1 h, proteins were precipitated with CHCl3/MeOH, samples were resuspended in 30 µL 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA and 90 µL of 1.33 mM maleimide-PEG 5 kDa were added. After 1 h, proteins were precipitated with CHCl3/MeOH, and resuspended in 1 x Laemmli sample buffer (Bio-Rad), boiled for 5 min at 95° C, separated by SDS-PAGE and analysed by Western blot. Viruses and cell lines A549 cells (ATCC: CCL-185), Vero E6 (ATCC: CRL-1586) and HEK293T cells (ATCC: CRL-1573) were cultured in complete DMEM made of Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), L-Glutamine (2 mg/mL, Gibco) and Penicillin-Streptomycin (100 U/mL, Gibco) and incubated at 37 °C in a humidified CO2 incubator. The ZIKV ATCC ® VR-1843™ was a gift of Vincent Calvez, Hospital Pitié-Salpêtrière, Paris, France. Agreement to work with infectious ZIKV was obtained in a Class III Biosafety Cabinet under BSL-3 conditions at the UB’L3 facility (INSERM US 005 – CNRS UMS 3427 – TBMcore, University of Bordeaux, France). A549 clone generation A549 cells clones used in this study were generated using a combination of lentivirus and retrovirus-based vectors. Lentiviral vector production was carried out by the Vect’UB service platform (INSERM US 005 – CNRS UMS 3427 – TBM-Core, University of Bordeaux, France). Lentiviral particles were generated by transient transfection of HEK293T cells using Lipofectamine 3000 (Thermo Fisher Scientific) following the manufacturer’s instructions. Subconfluent HEK293T cells were co-transfected with the lentiviral packaging plasmid psPAX2, the envelope plasmid pMD2.G-VSVG and the transfer plasmid encoding shRNA against RNAseK, pLKO.1-Puro-shRNAseK, to generate the A549 shRNAseK cells or the empty transfer vector pLKO.1-Puro to generate control A549 cells. Viral supernatants were harvested 48 h post-transfection and concentrated by ultracentrifugation. Then, A549 cells were transduced with optimised concentrations of lentiviral particles. After 48 h, cells were selected by culturing in medium supplemented with 10 µg/mL Puromycin for one week. Single-cell stably transduced clones were isolated by limiting dilution in 96-well plates and RNAseK knockdown efficiency in each clone was evaluated by RT-qPCR. Retroviral particles were produced by transient transfection of subconfluent HEK293T cells using Lipofectamine 3000 (Thermo Fisher Scientific) following the manufacturer’s instructions. Cells were co-transfected with the retroviral packaging plasmid pCL-Ampho and transfer plasmids pMXs-IRES-Blasticidin encoding either RNAseK-FLAG-WT-shRNA-resistant or RNAseK-FLAG-∆Palm-shRNA-resistant. Supernatants containing retroviral particles were collected 48 h post-transfection and concentrated by ultracentrifugation. A549 shRNAseK cells were subsequently transduced with retroviral particles encoding the respective constructs. Following transduction, cells were selected in medium containing 10 µg/mL Blasticidin for one week. Single-cell clones of A549 shRNAseK + RNAseK-FLAG-WT and A549 shRNAseK + RNAseK-FLAG-∆Palm were isolated by limiting dilution in 96-well plates. The expression levels of RNAseK and RNAseK-FLAG in each clone were quantified by RT-qPCR. Viral stock production The ZIKV strain was propagated by infecting Vero E6 cells at a multiplicity of infection (MOI) of 0.1. Infected cells were incubated at 37 °C and 5% CO2 in a humidified incubator for 72 h. Then, the culture supernatant was clarified by centrifugation (5 min at 1500 rpm) and aliquots were stored at - 80°C. Viral production was titrated using TCID50 (median tissue culture infectious dose) assay on Vero E6 cells. Viral infections A549 cells were seeded in 12-well plates 24 h prior to the experiment to reach approximately 90% confluence. Cells were pre-treated for 3 h with Bafilomycin A1 (Sigma-Aldrich) at a final concentration of 10 nM, as previously described [23] or Dynasore (Sigma-Aldrich) at a final concentration of 100 µM, as previously described [24], before ZIKV infection. Then, cells were infected with ZIKV at a multiplicity of infection (MOI) of 1. The infection medium consisted of the appropriate dilution of the ZIKV stock in Opti-MEM medium (Gibco), supplemented, where indicated, with Bafilomycin A1 (10 nM) or Dynasore (100 µM). After 2 h, the infection medium was removed and replaced with complete DMEM supplemented, where indicated, with the respective treatments. This time point was defined as 0 h post-infection (hpi). Non-infected control cells (Mock) were subjected to the same treatment conditions, except that fetal bovine serum (FBS) was used in place of the ZIKV stock. Both infected and Mock cells were incubated at 37 °C with 5% CO₂ in a humidified incubator for 72 h. Viral RNA purification and RT-qPCR analysis Viral RNA was purified from 200 µl of cell culture supernatant 72 hours post-infection (hpi) using High Pure Viral Nucleic Acid Kit (Roche Diagnostics) according to the manufacturer protocol. RNA was eluted into 50 µL of elution buffer. Each replicate of RT-qPCR assays was performed using 5 µL of RNA elution and GoTaq® 1-Step RT-qPCR System (Promega) in a CFX Opus 96 Real Time PCR System (Bio-Rad). The assays were performed using the following set of primers for detection of ZIKV viral genome: 5’-CCG CTG CCC AAC ACA AG-3’ (sense) and 5’-CCA CTA ACG TTC TTT TGC AGA CAT-3’ (antisense). The thermocycling conditions were: one retro-transcription step of 30 min at 50 °C, followed by one step of 10 min at 95 °C and 40 cycles of 15 s at 95 °C, 15 s at 60 °C and 15 s at 72 °C. TCID measurement A549 cells were seeded in a 6-well plate 24 h prior to the experiment to reach approximately 90% confluence. Viral titres were determined by adding serial dilutions of the viral suspensions (viral stock or supernatant from infected cells cultures) to A549 cells. Four replicates were performed. Plates were incubated at 37 °C with 5% CO₂ in a humidified incubator for 72 h. Then, cells were examined for cytopathic effect. Quantification of cytopathic effect was determined using the CellToxTM Green Cytotoxicity Assay (Promega) according to the manufacturer’s instructions. The level of fluorescence associated with the cytopathic effects was measured using a Victor Nivo plate reader (Perkin-Elmer). The TCID50/ml values were calculated according to the method of Reed and Muench [25]. Statistical analysis of TCID50 values was performed using a one-way ANOVA followed by Tukey’s post-hoc test for multiple comparisons in R with the tidyverse library. Data were log-transformed prior to analysis to meet ANOVA assumptions of normality and homoscedasticity. Flow cytometry Flow cytometry assays were performed to assess ZIKV infection in A549 cells. 72 h post-infection, cells were washed twice with 1 mL of PBS. Then, cells were harvested by treating each well with 400 µL of 0.05% trypsin solution and incubating at 37 °C for 10 min. Trypsinisation was stopped by adding 600 µL of DMEM supplemented with 10% FBS. Cells suspensions were homogenised by pipetting up and down. Cells were collected by centrifugation at 300 × g for 5 min and washed twice with 500 µL of PBS. After resuspension in 500 µL of PBS, fixation was performed by adding 500 µL of 8% paraformaldehyde in PBS and incubating at room temperature for 15 min. Fixed cells were collected by centrifugation at 300 × g for 5 min and washed twice with 500 µL of PBS. Permeabilization was carried out using 500 µL of 0.1% Triton X-100 in PBS for 10 min at room temperature, followed by two additional washes with 500 µL of PBS. Blocking was performed by incubating the cells with 500 µL of 5% FBS 0.01% Triton X-100 in PBS for 30 min at room temperature. Cells were then incubated with an anti-Flavivirus Envelope Protein antibody conjugated with Alexa Fluor™ 647 (BD Biosciences) diluted 1:300 in 300 µL of 5% FBS 0.01% Triton X-100 in PBS for 30 min at room temperature. After incubation, cells were collected by centrifugation at 300 × g for 5 min and washed twice with 500 µL of 5% FBS 0.01% Triton X-100 in PBS. Finally, cells were resuspended in 250 µL of 2% FBS in PBS and analysed by flow cytometry using a BD Accuri C6 Plus Flow Cytometer (BD biosciences) to assess the number of ZIKV infected cells. Differences in infection rates between conditions were assessed by one-way ANOVA followed by Tukey’s post-hoc test for multiple comparisons in R with the tidyverse library. Percentages were arcsine-square roots transformed to meet ANOVA assumptions. RT-qPCR for detection of specific mRNA A549 cells were cultured in 60 mm dishes until reaching approximately 80% confluence. Then, they were lysed using TRIzol reagent (Invitrogen) and total RNA was extracted according to the manufacturer’s instructions. RT-qPCR assays were performed using 5 µL of the extracted RNA and the GoTaq® 1-Step RT-qPCR System (Promega) on a CFX Opus 96 Real-Time PCR System (Bio-Rad). The following primer sets were used: for RNAseK mRNA detection 5’-TGG GGA GTG ATC ATG TTG ATA ATG-3’ (sense) and 5’-GCG CTT ATT GAG CCG AAC TT-3’ (antisense); for RNAseK-FLAG mRNA, 5’-AAT GGC CCC CAG AAT ATC-3’ (sense) and 5’-TCG TCG TCA TCC TTG TAA TC-3’ (antisense); and for the reference gene succinate dehydrogenase (SDH) 5’-ATC CAC TAC ATG ACG GAG CAG-3’ (sense) and 5’-GGT ATC ATA TCG CAG AGA CCT TCC-3’ (antisense) or h28S rRNA 5’-GGG TGG TAA ACT CCA TCT AAG G-3’ (sense) and 5’-GCC CTC TTG AAC TCT CTC TTC-3’ (antisense). The thermocycling conditions for all reactions were: reverse transcription for 30 min at 50 °C, followed by an initial denaturation at 95 °C for 10 min, and 40 cycles of 15 s at 95 °C, 15 s at 62 °C, and 15 s at 72 °C. Statistical comparisons of relative mRNA expression between conditions were performed using one-way ANOVA followed by Tukey’s post-hoc test for multiple comparisons in R with the tidyverse library. ΔCt values were log-transformed to satisfy ANOVA assumptions. Alternatively, in order to quantify the level of expression of RNAseK during ZIKV infection in A549 cells stably transfected with RNAseK-FLAG variant, total RNA was isolated from the corresponding ZIKV infected cell cultures, using the High Pure RNA isolation Kit (Roche) according to the manufacturer’s protocol. RNA quantification was performed by RT-qPCR using the GoTaq® 1-Step RT-qPCR System kit (Promega). The following primer sets were used: for RNAseK-FLAG mRNA, 5’-AAT GGC CCC CAG AAT ATC-3’ (sense) and 5’-TCG TCG TCA TCC TTG TAA TC-3’ (antisense), and for the reference genes succinate dehydrogenase (SDH) mRNA 5’-ATC CAC TAC ATG ACG GAG CAG-3’ (sense) and 5’-GGT ATC ATA TCG CAG AGA CCT TCC-3’ (antisense), or h28S rRNA 5’-GGG TGG TAA ACT CCA TCT AAG G (sense) and 5’-GCC CTC TTG AAC TCT CTC TTC-3’ (antisense). The amplification protocol started with a reverse transcription step at 50 °C for 30 min, followed by an initial denaturation at 95 °C for 10 min. This was followed by 40 amplification cycles consisting of denaturation at 95 °C for 10 s, annealing at 60 °C for 10 s, and extension at 72 °C for 10 s. A melting curve analysis was performed by increasing the temperature at 0.5 °C per second from 60 °C to 95 °C. Immunofluorescence assays HEK293T cells grown on glass coverslips to 80% confluence were transiently transfected with 1.5 µg of plasmid encoding RNAseK-FLAG-WT or 3 ug of plasmid encoding RNAseK-FLAG-ΔPalm using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. A higher amount of RNAseK-FLAG-ΔPalm plasmid was used to compensate for its lower stability, enabling the detection of this mutant protein by immunofluorescence. After 24 h, cells were fixed in 4% paraformaldehyde–PBS for 20 min at room temperature and permeabilised with 0.1% Triton X-100 in PBS for 5 min. When applicable, before fixation, cells were incubated for 5 min with CellBrite® Fix 640 Membrane Stain (1:2000 in PBS, Biotium). After two PBS washes, coverslips were incubated overnight at 4 °C with the appropriate primary antibody mix. Primary antibodies: rat anti-FLAG (anti-DYKDDDDK Tag, L5 clone, BioLegend), rabbit anti-Calnexin (10427-2-AP, Proteintech), mouse anti-GM130 (BDB610822, clone 35/GM130, BD Biosciences), mouse anti-Rab7 (sc-376362, Santa Cruz), mouse anti-LAMP1 (sc-20011, Santa Cruz), and rabbit anti-EEA1 (2411 S, Cell Signaling). Samples were then incubated for 1 h at 37 °C with the following secondary antibodies: goat anti-rat IgG Alexa Fluor™ 488 (4416, Cell Signaling), goat anti-rabbit IgG Alexa Fluor™ 555 (A-21428, Thermo Fisher) and goat anti-mouse IgG Alexa Fluor™ 555 (A-21422, Thermo Fisher). Nuclei were counterstained with DAPI, and coverslips were mounted using SlowFade™ reagent (Thermo Fisher Scientific). Fluorescence images were acquired on a Carl Zeiss LSM880 confocal microscope (Germany) using a 63× NA 1.4 Plan-Apochromat oil immersion objective and sequential acquisition mode (Bordeaux Imaging Center). Quantitative colocalisation analysis Image analysis was performed using FIJI v1.52 (Schindelin et al., 2012). Background subtraction and colocalisation quantification were conducted with the “Image Threshold” and “Coloc2” plugins. Images were obtained randomly and analysed in a blinded manner with respect to experimental conditions. At least 30 fluorescence positive images per coverslip were analysed to obtain a representative sample for each condition. Thresholding parameters for each protein marker analysed were applied uniformly across all images within each experiment. Mander’s coefficients were calculated to evaluate the degree of colocalisation between RNAseK variants and organelle markers. Statistical comparisons of Mander’s coefficients were performed using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons in R (tidyverse package). Percentages were arcsine–square roots transformed to meet ANOVA assumptions. Proteasome inhibition assay Cells were cultured in 60 mm dishes until reaching approximately 80% confluence. Then, they were treated with the proteasome inhibitor MG-132 (Sigma-Aldrich) at a final concentration of 10 µM for 24 h, as previously described [26]. Following treatment, cells were harvested and whole-protein extracts were prepared using RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% SDS), supplemented with an EDTA-free protease inhibitor cocktail (Roche). Cell lysates were mixed with 4X Laemmli Sample Buffer (Bio-Rad) and specific protein expression levels were analysed by Western blot assays. Cycloheximide chase assays HEK293T cells were cultured in 60 mm dishes until reaching approximately 70–80% confluence. Then, cells were transfected with one of the following plasmids: pcDNA-RNAseK-FLAG-WT (1.5 µg), pcDNA-RNAseK-FLAG-∆Palm (3 µg) or the empty vector pcDNA (1.5 µg), using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. The amount of DNA used for RNAseK-FLAG-WT was reduced by half compared with RNAseK-FLAG-∆Palm to achieve expression levels comparable to those of the other constructs. 24 h post-transfection, cells were treated with the protein synthesis inhibitor Cycloheximide (Sigma-Aldrich) at a final concentration of 10 µg/mL for 0, 6, 12, or 24 h, as previously described [27]. After treatment, cells were harvested and whole-cell protein extracts were prepared using RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% SDS) supplemented with an EDTA-free protease inhibitor cocktail (Roche). Cell lysates were mixed with 4X Laemmli Sample Buffer (Bio-Rad) and protein expression levels were analysed by Western blot assays. Western blot assays Equivalent quantities of protein lysates were separated by SDS-PAGE and transferred onto 0.22 μm nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk in TBS-T (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature and incubated overnight at 4 °C in a dilution 1/1000 in blocking buffer with one of the following primary antibodies: anti-FLAG® antibody (F7425, Merck), anti-ATP6V0D1 antibody (18274-1-AP, Proteintech), anti-ATP6V0A1 antibody (13828-1-AP, Proteintech), anti-ATP6V1A antibody (17115-1-AP, Proteintech) or anti-Alpha Tubulin antibody (11224-1-AP, Proteintech). After three washes with TBS-T, membranes were incubated with HRP-conjugated goat anti-rabbit IgG secondary antibody (111-035-144, Jackson ImmunoResearch) diluted 1/5000 in blocking buffer, for 1 h at room temperature. Following three additional washes with TBS-T, signal detection was performed using Immobilon® Crescendo Western HRP substrate (Merck) according to the manufacturer’s instructions and protein bands were visualised using the ChemiDoc MP Imaging System (Bio-Rad). In silico protein stability prediction We predicted the effect on protein structure and molecular stability of the four non-synonymous Cysteine-to-Alanine substitutions present in RNAseK-ΔPalm mutant relative to the wild-type RNAseK (RNAseK-WT). For this, FoldX 5.0 software [28] was run locally to estimate the change in the Gibbs free energy of protein folding (ΔΔG) introduced by these mutations using the protein structure of RNAseK-WT (PDB ID: 6WM2) as a reference (ΔΔG = ΔG_RNAseK-ΔPalm − ΔG_RNAseK-WT). The combined effect of all four substitutions was evaluated using the BuildModel function of FoldX. ΔΔG calculations were executed on previously optimised structures and were performed 5 times. The reported ΔΔG value represent the average of these independent runs. Other parameters were set to default. Predicted ΔΔG values were classified as stabilizing ( < − 1.5 kcal/mol), neutral (− 1.5 to + 1.5 kcal/mol), or destabilizing ( > + 1.5 kcal/mol), based on the experimental standard error of the method (0.46 kcal/mol) [29]. Acyl biotin exchange Acyl biotin exchange was performed as described previously with small modifications [30]. A549 cells stably expressing RNAseK-FLAG-WT were infected with ZIKV (MOI 1) and harvested at 0, 1, 5, 24, 48, and 72 h post infection. Non-infected (NI) cells were used as controls. For infection, ZIKV was added onto cells for 1 h, after which the media was removed and replaced with complete medium. The time point designated as 0 h corresponds to the moment immediately following removal of the viral inoculum. Thus, NI and 0 h samples are distinct conditions. Cells were harvested, washed twice with ice-cold PBS, flash-frozen, and stored at − 80 °C. For lysis, frozen cells were resuspended in 4% SDS, 150 mM NaCl, 50 mM triethanolamine (TEA) pH 7.4, 1 mM EDTA, benzonase, EDTA-free protease inhibitor (Roche). Lysates (200 µg) were diluted to 92.5 µL with 150 mM NaCl, 50 mM TEA pH 7.4. 5 µL of 200 mM neutralised TCEP (Thermo, final concentration of 10 mM TCEP) were added and incubated at room temperature for 30 min with end-over-end rotation. 2.5 µL N-ethylmaleimide (1 M stock in ethanol, freshly prepared, 25 mM final concentration) were added and the solution was incubated for 2 h at room temperature. Proteins were precipitated by CHCl3/MeOH precipitation. The protein pellets were allowed to air-dry for 5–10 min, resuspended in 92.5 µL of 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA. The reduction/alkylation was repeated and proteins were precipitated with CHCl3/MeOH (2x). Proteins were resuspended in 40 µL 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 2.5 mM EDTA. 20 µL HPDP-biotin 5 mM (DMF: DMSO 4:1) and 40 µL 2.5 M hydroxylamine pH (1 M final) were added. The samples were incubated with end-other end rotation for 1h30, and precipitated by CHCl3/MeOH precipitation. Proteins were resuspended in 20 µL 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA. The samples were diluted to 100 µL with 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA. For each sample, 20 µL (40 µg) were transferred to a 1.5 mL microcentrifuge tube (Input). 7 µL of sample loading buffer (Laemmli 4x: BME 9:1) were added and the samples were boiled for 5 min. 80 µL of 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA were added to the rest of the samples (160 µg, final SDS concentration 0.4%). Samples were added to 10 µL of high-affinity neutravidin-agarose beads (Thermo) (pre-washed 3 × 0.5% SDS TEA) and were incubated with end-over-end rotation for 1h30. Samples were centrifuged at 4,000 xg for 30 s, the supernatants were discarded and the beads washed 3 × 0.5% SDS 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA. The supernatants were discarded. 14 µL TEA buffer 4% SDS, 50 mM TEA pH 7.4, 150 mM NaCl, 1 mM EDTA and 14 µL sample loading buffer (Laemmli 4x: BME 9:1) were added. Samples were boiled for 5 min (S-palmitoylated). Typically, 4 x of S-palmitoylated samples were loaded compared to input. Lysosomal pH measurement by live-cell fluorescence microscopy To assess lysosomal pH in living cells, a genetically encoded ratiometric lysosomal pH sensor based on a pHluorin-LAMP1-mApple fusion protein was used, following approaches previously described for lysosomal pH imaging with LAMP1-targeted fluorescent reporters [32] https://doi.org/10.1002/advs.202300244. Two days prior to imaging, A549 parental control cells, A549 cells silenced for RNAseK (shRNAseK), and A549 shRNAseK cells stably reconstituted with either wild-type RNAseK (RNAseK-WT) or a palmitoylation-deficient mutant (RNAseK-Δpalm) were seeded in 35-mm glass-bottom dishes to reach approximately 80% confluence after 24 h. As a positive control for lysosomal dysfunction, an additional group of A549 cells was seeded to be treated with Bafilomycin A1 (10 nM) for 3 h prior to image acquisition. The following day, cells were transiently transfected with a plasmid encoding pHluorin-LAMP1-mApple, which targets the late endosomal/lysosomal membrane protein LAMP1 fused to two fluorescent reporters: the pH-insensitive fluorophore mApple (excitation 568 nm / emission 592 nm) and the pH-sensitive fluorophore pHluorin (excitation 488 nm / emission 511 nm). This dual reporter allows ratiometric estimation of lysosomal luminal pH. 24 h after transfection, cells were washed twice with PBS to remove residual culture medium that could interfere with fluorescence imaging. The medium was then replaced with Hank’s Balanced Salt Solution (HBSS) containing 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na₂HPO₄, 5.55 mM glucose, 0.44 mM KH₂PO₄, 1.3 mM CaCl₂, 1.0 mM MgSO₄, and 4.2 mM NaHCO₃. For the lysosomal inhibition control condition, Bafilomycin A1 (10 nM) was added to the HBSS medium 3 h prior to imaging and maintained during image acquisition. Live-cell fluorescence imaging was performed while maintaining the samples at 37 °C and 5% CO₂ throughout the acquisition period. Images were acquired using a Leica DMI6000B spinning-disk confocal microscope operating in sequential acquisition mode. A 63× oil-immersion objective (NA 1.4, plan apochromat) was used for all experiments. Images were recorded using a 16-bit dynamic range to maximize sensitivity for subsequent quantitative analysis.Images were obtained randomly and analysed in a blinded manner with respect to experimental conditions. At least 35 fluorescence positive images per condition were acquired, and three independent biological replicates were performed. Image analysis was carried out using FIJI software (v1.52). The pre-installed plugin “Image threshold” with the “Default” model was used to subtract the background. Lysosomes were identified based on the mApple signal, which was used to define regions of interest (ROIs) corresponding to individual lysosomes. For each ROI, the area-normalized fluorescence intensity (mean intensity, MI) was measured for both the pH-sensitive channel (pHluorin, MI511) and the pH-insensitive reference channel (mApple, MI592). Lysosomal pH changes were estimated by calculating the MI ratio between the two channels for each ROI (MI511 / MI592). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. Data from three independent experiments were used for all statistical analyses. Results RNAseK has four S-palmitoylation sites In a previous study [20], we identified three S-palmitoylation sites on RNAseK (Cys6, Cys7, and Cys85) by proteomic analysis (Figure S1, Fig. 1A). Given that RNAseK is a small 11 kDa transmembrane protein containing two transmembrane domains and five cysteine residues in total (Fig. 1A), the observation that at least three of these cysteines are S-palmitoylated, suggests an important role for this lipid modification in RNAseK function. To validate these findings and investigate whether the remaining cysteine residues could also be S-palmitoylated, we designed a mutagenesis screening approach in which each cysteine in RNAseK was mutated to alanine, either individually or in combination. For this, HEK293T cells were transfected with plasmids encoding FLAG-tagged RNAseK variants to facilitate detection. To assess the S-palmitoylation levels of each RNAseK-FLAG variant, we employed two independent methods. First, we used a metabolic labelling approach with alk-16, an alkyne-modified palmitate analogue. Cells expressing RNAseK-FLAG variants incorporated alk-16 into the S-palmitoylation sites of RNAseK. Subsequently, RNAseK was immunoprecipitated via its FLAG tag, and alk-16 labelled cysteine residues were detected by copper-catalysed azide-alkyne cycloaddition (CuAAC) using an azido-fluorophore (Fig. 1B) [31]. As expected, a fluorescent signal was observed in cells expressing wild-type RNAseK, confirming its S-palmitoylation (Fig. 1C, Figure S2). Alanine substitution of Cys6, Cys7, and Cys85 (Cys6/7/85A) reduced the fluorescence intensity but did not abolish it, indicating the presence of additional palmitoylation sites. In contrast, mutation of all five cysteines or of Cys6/7/14/85 eliminated fluorescence, whereas substitution of Cys6/7/69/85 did not. These findings indicate that Cys14, but not Cys69, is an additional S-palmitoylation site on RNAseK. RNAseK is S-palmitoylated at four cysteine (Cys) residues. (A) Amino acid sequence of RNAseK. Transmembrane domains are underlined. RNAseK contains five cysteine residues. Mass spectrometry analysis identified S-palmitoylation at Cys6, Cys7, and Cys85 (highlighted in yellow, see also Figure S1) [20]. Cys14 and Cys69 are highlighted in green and purple, respectively. (B) Schematic representation of the IP/Click assay. Cells were metabolically labelled with alk-16, an alkyne-modified palmitate analogue, followed by immunoprecipitation (IP) and copper-catalysed azide-alkyne cycloaddition (CuAAC) to couple azido-TAMRA-biotin for detection. (C) Cells transfected with empty vector (EV), RNAseK-FLAG-WT or Cysteine-to-Alanine mutants were subjected to the IP/Click assay. Input: whole cell lysate. Equal amounts of total protein were loaded per condition (GAPDH, loading control). Data shown are representative of biological duplicates. (D) Schematic representation of the Acyl-PEG exchange (APE) assay [30]. Free Cys are first blocked with N-ethylmaleimide (NEM). S-palmitoyl groups are then cleaved with hydroxylamine (NH₂OH), revealing previously modified cysteines, which are subsequently labelled with 5 kDa mPEG-maleimide (mPEG-mal). Each palmitoylated Cys results in a detectable band shift. (E) APE assay performed on cells transfected with EV, RNAseK-FLAG-WT, or Cysteine-to-Alanine mutants. Red stars indicate band shifts corresponding to the number of S-palmitoylation events (apo = non S-palmitoylated, 1 star = 1 palmitoylated Cys, 2 stars = 2 palmitoylated Cys and 3 stars = 3 palmitoylated Cys). A blue arrow indicates background bands. Equal amounts of total protein were loaded per condition. Data shown are representative of biological duplicates To further support these findings, we performed an Acyl-PEG Exchange (APE) assay [30]. In protein lysates from HEK293T cells transfected with each RNAseK variant, free Cys were capped with N-ethylmaleimide, S-palmitoylated Cys were hydrolysed with hydroxylamine treatment, and the newly exposed Cys were alkylated with 5 kDa maleimide-PEG (mPEG-mal). The incorporation of mPEG-mal at S-palmitoylation sites resulted in a characteristic band shift detectable by SDS-PAGE and Western blotting (Fig. 1D). Up to three distinct shifts were observed for wild-type RNAseK (Fig. 1E, Figure S2). A fourth shift was not detected, potentially due to steric hindrance and incomplete simultaneous S-palmitoylation of all sites. Consistent with alk-16 labelling, mutation of Cys6/7/85 reduced the number of shifted bands but one band shift remained, indicating the presence of another S-palmitoylation site. Again, the absence of band shifts in the mutant lacking all five Cys or Cys 6/7/14/85, but not in the mutant lacking Cys 6/7/69/85 confirmed Cys14 as the fourth S-palmitoylation site. Together, these results demonstrate that RNAseK is S-palmitoylated on four cysteine residues: Cys6, Cys7, Cys14, and Cys85. Interestingly, a severe decrease in fluorescence in the IP/Click experiment was observed in three constructs: Cys6/14/85A, Cys7/14/85A, and Cys14/85A. Because Cys14 and Cys85 are mutated in all three cases, this suggests that Cys14 and/or Cys85 represent major sites of S-palmitoylation. This interpretation is further supported by the Acyl-PEG exchange assay, in which the intensity of the first upper band is noticeably reduced in these samples. The loss of Cys14/85 may impair protein stability and/or alter the ability of the remaining cysteines (Cys6 and Cys7) to undergo S-palmitoylation. RNAseK S-palmitoylation is necessary for efficient ZIKV infection in human cells To investigate the role of RNAseK S-palmitoylation during ZIKV infection, we generated A549 human cell lines stably expressing a short hairpin RNA targeting RNAseK mRNA (shRNAseK), with the aim to silence endogenous RNAseK expression. We then restored the expression of shRNAseK-resistant variants of RNAseK, either wild-type (RNAseK-FLAG-WT) or a S-palmitoylation-deficient mutant (RNAseK-FLAG-ΔPalm) in which the four S-palmitoylation sites (Cys6, Cys7, Cys14, and Cys85) were substituted by Ala residues. These modified cell lines were subsequently infected with ZIKV at a multiplicity of infection (MOI) of 1. As experimental controls, A549 parental cells were treated with vehicle (DMSO), Dynasore (100 µM), a compound that inhibits viral entry independently of endosomal acidification, or Bafilomycin A1 (10 nM), a known inhibitor of the v-ATPase complex.RNAseK was recently identified as a novel component of the v-ATPase complex [13] . At 72 h post-infection (hpi), the percentage of infected cells was quantified by flow cytometry (Fig. 2A, Figure S3). S-palmitoylation of RNAseK is relevant for ZIKV infection. A549 cells stably expressing either RNAseK-FLAG-WT or RNAseK-FLAG-∆Palm, A549 control cells, A549 shRNAseK knockdown cells and A549 cells treated with Bafilomycin A1 (10 nM) or Dynasore (100 µM), were infected with ZIKV at a multiplicity of infection (MOI) of 1 for 72 h. Subsequently, culture supernatants were collected for RT-qPCR and TCID50 assays, while cells were harvested for flow cytometry analysis. (A) The barplot depicts the percentage of Zika virus-infected cells detected by flow cytometry analysis at 72 hpi. Infected cells were stained with an anti-Flavivirus Envelope antibody. Data are presented as mean ± standard deviation from three independent biological replicates. ND = Non-Detectable. A one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons (p < 0.01) was performed. Asterisks indicate significant differences between experimental conditions and the control A549 cells. (B) Barplot representing the viral RNA levels determined by RT-qPCR for each condition. Data are presented as mean ± standard deviation from three independent biological replicates. ND = Non-Detectable. Data were normalised to ZIKV infected A549 control cells. A one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons (p < 0.01) was performed. Asterisks indicate significant differences between experimental conditions and the control A549 cells. (C) Barplot representing the viral titre estimated using the TCID50 assay for each condition. Data are presented as mean ± standard deviation from three independent biological replicates. ND = Non-Detectable. A one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons (p < 0.01) was performed. Asterisks indicate statistically significant differences relative to the control A549 cells As expected, both Bafilomycin A1 and Dynasore treatments significantly reduced the percentage of ZIKV-infected cells (Fig. 2A). Interestingly, RNAseK knockdown and reconstitution with the palmitoylation-deficient mutant (A549 shRNAseK + RNAseK-FLAG-ΔPalm) also led to a marked reduction in the number of infected cells compared to control A549 cells. In contrast, reconstitution with wild-type RNAseK (A549 shRNAseK + RNAseK-FLAG-WT) restored infection levels to slightly above those of the control condition. In addition, in order to evaluate new viral production in each condition, aliquots of the culture supernatant were collected and viral RNA genomes were quantified by RT-qPCR. In agreement with the flow cytometry data, Bafilomycin A1 and Dynasore drastically reduced the amount of viral RNA in the supernatant (Fig. 2B). Similarly, RNAseK knockdown and reconstitution with the palmitoylation-deficient mutant (A549 shRNAseK + RNAseK-FLAG-ΔPalm) significantly decreased the level of viral genome detected, whereas reconstitution with RNAseK-FLAG-WT (A549 shRNAseK + RNAseK-FLAG-WT) showed a viral RNA level slightly higher than the control cells. Moreover, with the aim of assessing whether the viral particles produced were fully mature and infectious, a TCID50 assay was performed. Supernatants from each condition were used to infect A549 cells and the cytopathic effect generated was measured in each condition. The viral titres calculated in each condition were in concordance with the previously described results. RNAseK knockdown and reconstitution with the palmitoylation-deficient mutant (A549 shRNAseK + RNAseK-FLAG-ΔPalm) generated lower viral titres than the control condition, while reconstitution with RNAseK-FLAG-WT (A549 shRNAseK + RNAseK-FLAG-WT) showed higher viral titres than the control condition. Taken together, these findings demonstrate that both the presence of RNAseK and its S-palmitoylation are necessary for efficient ZIKV infection in human cells. S-palmitoylation does not affect the subcellular localisation of RNAseK S-palmitoylation can alter the physicochemical properties of target proteins, often increasing their membrane affinity and influencing their subcellular localisation [9]. To test whether S-palmitoylation affects RNAseK localisation, HEK293T cells were transiently transfected with plasmids encoding either RNAseK-FLAG-WT or RNAseK-FLAG-ΔPalm. After 24 h, cells were fixed and immunofluorescence assays were performed to detect RNAseK variants together with organelle-specific host markers. Quantitative colocalisation analyses were performed to evaluate potential differences in subcellular distribution (Fig. 3). Six different organelle markers were used to assess RNAseK localisation across six membrane-bound compartments: plasma membrane, endoplasmic reticulum (ER), Golgi apparatus, early endosomes, late endosomes, and lysosomes. No significant differences in localisation were observed between RNAseK-FLAG-WT and ΔPalm in any compartment. Both variants showed minimal colocalisation with the plasma membrane marker (CellBrite; Fig. 3), while exhibiting strong colocalisation with ER and Golgi markers (Calnexin and GM130, respectively; Fig. 3). For Calnexin, both Mander’s coefficients were high, indicating that most of the expressed RNAseK localised to the ER membrane. The strong colocalisation of RNAseK with the ER marker (Calnexin) may result from the use of strong viral promoters (pCMV) in the plasmids used for transient transfection, which drive high expression levels. This could lead to accumulation of the protein at its site of synthesis after saturation of its usual cellular destinations and transport pathways. In the case of the Golgi apparatus (GM130), both variants were present in high levels in this compartment, although the Mander’s coefficients indicate that they were relatively more present in other compartments. Regarding vesicular transport compartments, both RNAseK variants were more abundant in late endosomes (Rab7) and lysosomes (LAMP1) than in early endosomes (EEA1). Altogether, these results suggest that the subcellular localisation of RNAseK is not affected by its S-palmitoylation (Fig. 3). Subcellular localisation of RNAseK-FLAG variants. (A) HEK293T cells were transiently transfected with plasmids encoding either RNAseK-FLAG-WT or RNAseK-FLAG-ΔPalm. Cells were fixed 24 h post-transfection and subjected to immunofluorescence assays to detect RNAseK variants along with organelle-specific markers. Representative images are shown: RNAseK-FLAG (green), organelle markers (red), and nuclei stained with DAPI (blue). Colocalisation between RNAseK-FLAG and organelle markers is indicated in yellow. Scale bar, 10 µm. (B) Quantitative colocalisation analysis between RNAseK-FLAG variants and the different organelle markers. Box plots show Mander’s coefficients for each RNAseK-FLAG/marker pair. At least 30 fluorescence-positive images per coverslip were analysed for each condition. A one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons (p < 0.01) was performed. No significant differences were observed between RNAseK-FLAG-WT and RNAseK-FLAG-ΔPalm under any evaluated condition. S-palmitoylation of RNAseK is required for protein stability and prevents proteasomal degradation To decipher how the S-palmitoylation of RNAseK is involved in the phenotypes observed during ZIKV infection, we further investigated the possibility that this post-translational modification affects the intracellular stability or turnover of the protein. To address this, we performed a cycloheximide chase assay. HEK293T cells were transiently transfected with plasmids encoding either RNAseK-FLAG-WT, RNAseK-FLAG-ΔPalm, or an empty vector control. After 24 h, cells were treated with cycloheximide (10 µg/mL) for 0, 6, 12, or 24 h. Cycloheximide inhibits de novo protein synthesis in eukaryotic cells, enabling assessment of the degradation kinetics of pre-existing proteins. Western blot analysis of these cell lysates revealed a significant reduction in the stability of the RNAseK-FLAG-ΔPalm mutant compared to the RNAseK-FLAG-WT (Fig. 4A, Figure S4). While RNAseK-FLAG-WT protein remained detectable for up to 24 h post-treatment, the ΔPalm mutant was only detectable until 12 h, suggesting that S-palmitoylation is necessary to maintain RNAseK intracellular stability over time. S-palmitoylation of RNAseK prevents its degradation by the proteasome (A) HEK293T cells were transfected with plasmids encoding either RNAseK-FLAG-WT, RNAseK-FLAG-ΔPalm or the empty vector (-). 24 h post-transfection, cells were treated with Cycloheximide (10 µg/mL) for 0, 6, 12, or 24 h. Subsequently, cells were harvested and whole-protein lysates were separated by SDS-PAGE. Overexpressed RNAseK-FLAG-WT and ΔPalm were detected by Western blot using an anti-FLAG antibody. Equal amounts of total protein were loaded per condition. Alpha-tubulin was used as a loading control. Results are representative of three independent biological replicates. (B) A549 cells stably expressing either RNAseK-FLAG-WT or RNAseK-FLAG-∆Palm as well as A549 control cells and A549 shRNAseK knockdown cells, were treated with either vehicle control (DMSO) or the proteasome inhibitor MG-132 (10 µM) for 24 h. Subsequently, cells were harvested and whole-protein lysates were separated by SDS-PAGE. Proteins of interest were detected by Western blot using specific antibodies. Equal amounts of total protein were loaded per condition. Alpha-tubulin was used as a loading control. Results are representative of three independent biological replicates To further support these observations, we performed a proteasome inhibition assay. For this, A549 cells stably expressing either RNAseK-FLAG-WT or RNAseK-FLAG-ΔPalm, along with parental A549 and A549 shRNAseK knockdown lines as controls, were treated with either vehicle (DMSO) or the proteasome inhibitor MG-132 (10 µM) for 24 h. Interestingly, Western blot analysis of these cell lysates indicated that RNAseK-FLAG-ΔPalm was only detectable upon proteasome inhibition, whereas the RNAseK-FLAG-WT variant was present under both conditions (Fig. 4B, Figure S4). These findings indicate that S-palmitoylation protects RNAseK from proteasomal degradation. Moreover, since RNAseK has recently been described as a novel subunit of the v-ATPase complex [13], we also assessed whether its S-palmitoylation state impacts the expression levels of other subunits within this complex. Our results show that neither the silencing of RNAseK nor reintroduction of either RNAseK-FLAG-WT or RNAseK-FLAG-ΔPalm altered the expression of other v-ATPase subunits under the tested conditions (Fig. 4B). In addition, to evaluate whether the observed differences in RNAseK stability were attributable to the absence of S-palmitoylation rather than the introduced Cys to Ala mutations, we performed an in silico stability analysis. Using FoldX, we predicted the impact of individual and combined cysteine-to-alanine mutations on RNAseK folding energy. The ΔΔG for the quadruple mutant (C6A, C7A, C14A, C85A) was approximately − 2.5 kcal/mol, a value considered stabilizing compared to the WT variant (Figure S5). These data support that the observed destabilisation of RNAseK-FLAG-ΔPalm results from the absence of S-palmitoylation rather than the mutations themselves. Together, these findings indicate that S-palmitoylation contributes to RNAseK protein stability and protects it from proteasomal degradation. S-palmitoylation of RNAseK is required for lysosomal acidification As a member of the v-ATPase complex, RNAseK is likely involved in endosomal acidification processes. To assess whether loss of RNAseK S-palmitoylation affects lysosomal pH, we performed live-cell microscopy using a genetically encoded ratiometric lysosomal pH sensor based on the tandem fluorescent reporter pHLuorin-LAMP1-mApple (Fig. 5A), as previously described for LAMP1-targeted lysosomal pH imaging [32]. Effect of RNAseK S-palmitoylation on lysosomal acidification assessed by live-cell imaging. (A) Schematic illustration of the ratiometric lysosomal pH reporter pHLuorin-LAMP1-mApple. (B) Representative live-cell fluorescence microscopy images of A549-derived cell lines stably expressing the indicated RNAseK variants and transiently transfected with pHLuorin-LAMP1-mApple. mApple fluorescence is shown in red, pHLuorin fluorescence in green, and merged signals in yellow. Scale bar, 10 µm. (C) Quantitative analysis of fluorescence signals from mApple (MI₅₉₂) and pHLuorin (MI₅₁₁). The ratio of pHLuorin (MI₅₁₁) to mApple (MI₅₉₂) fluorescence intensity was calculated for each condition and normalized to parental A549 cells. Bar graphs show mean ± SD from three independent biological replicates. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons (p < 0.01). Asterisks indicate statistically significant differences relative to parental A549 control cells. Increased pHLuorin/mApple ratios indicate reduced lysosomal acidification. Parental A549 cells, RNAseK-silenced A549 cells (shRNAseK), and shRNAseK cells stably reconstituted with either wild-type RNAseK (RNAseK-WT) or a S-palmitoylation-deficient mutant (RNAseK-ΔPalm) were transiently transfected with the pHLuorin-LAMP1-mApple construct. A549 cells treated with Bafilomycin A1 (10 nM) were included as a positive control for lysosomal dysfunction. This reporter localizes to LAMP1-positive late endosomal/lysosomal membranes and combines the pH-insensitive fluorophore mApple (excitation 568 nm / emission 592 nm) with the pH-sensitive fluorophore pHLuorin (excitation 488 nm / emission 511 nm), enabling ratiometric measurement of lysosomal luminal pH (Fig. 5A). Lysosomes were identified based on the mApple signal to define regions of interest (ROI) corresponding to individual vesicles. For each ROI, mean fluorescence intensity was quantified in both channels, and lysosomal pH changes were estimated as the MI511 / MI592 ratio, normalized to parental A549 cells. As expected, treatment with Bafilomycin A1 for 3 h prior to imaging induced lysosomal dysfunction, as shown by a marked increase in pHLuorin fluorescence (Fig. 5B) and a significant elevation of the MI511 / MI592 ratio relative to parental A549 cells (Fig. 5C). A similar, although less pronounced, phenotype was observed in RNAseK-silenced cells and in cells expressing RNAseK-Δpalm. In contrast, reconstitution with RNAseK-WT restored the MI511 / MI592 ratio to levels comparable to parental A549 cells, indicating normal lysosomal pH. Together, these data suggest that the absence of RNAseK S-palmitoylation increases lysosomal pH, likely promoting lysosomal dysfunction in a manner comparable to RNAseK silencing. These findings are consistent with our previous results showing that loss of RNAseK S-palmitoylation increases protein degradation, producing a phenotype closely resembling RNAseK knockdown. ZIKV infection reduces RNASEK levels and increases its S-palmitoylation To assess S-palmitoylation of RNAseK-FLAG following ZIKV infection, an acyl–biotin exchange assay was performed at multiple time points post-infection (0–72 hpi, MOI 1) in A549 cells stably expressing RNAseK-FLAG-WT (Fig. 6, Figure S6). We observed an increase in S-palmitoylation of RNAseK-FLAG-WT upon infection, despite a concomitant decrease in total RNAseK-FLAG-WT protein levels. In the same conditions, RNAseK-FLAG-ΔPalm remained undetectable by Western blot (Fig. 4B, Figure S7A). We also evaluated changes in RNAseK-FLAG-WT expression during ZIKV infection by RT-qPCR (Figure S7B). RNAseK-FLAG-WT mRNA levels decreased progressively over time post-infection. These results suggest that the reduction in total RNAseK-FLAG-WT protein levels is likely attributable to reduced RNAseK-FLAG-WT mRNA levels. S-palmitoylation of RNAseK increases upon ZIKV infection, while total RNAseK levels decrease. Time-course of RNAseK S-palmitoylation after ZIKV infection. An acyl-biotin exchange assay was performed to assess S-palmitoylation levels of RNAseK-FLAG-WT after 0- 72 hpi of ZIKV infection in A549 cells stably expressing RNAseK-FLAG-WT. NI refers to non-infectedcells processed in parallel, whereas 0 hpi corresponds to infected cells harvested immediately after the 2 h infection period (virus adsorption and entry) and medium replacement, prior to significant viral replication. (A) Western blots showing S-palmitoylated (S-palm) RNAseK-FLAG-WT and overall RNAseK-FLAG-WT protein (Input). (B) S-palmitoylated RNAseK-FLAG-WT values in the graph were derived from S-acylated RNAseK-FLAG-WT normalised to RNAseK-FLAG-WT “Input” and β-actin as a loading control. (NI = non-infected). Data are presented as mean ± standard deviation from four independent biological replicates, with individual data points shown. Statistical comparisons were performed using an unpaired Student’s t-test versus the NI condition: * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant. Taken together, these findings indicate that although RNAseK expression declines during ZIKV infection, the relative increase in RNAseK S-palmitoylation may counterbalance this reduction by stabilizing the remaining protein pool. Given our previous results showing that S-palmitoylation protects RNAseK from proteasomal degradation and promotes ZIKV infection, these data support a model in which enhanced RNAseK S-palmitoylation during infection contributes to viral replication. Discussion The role of RNAseK in flavivirus infection was initially identified in genome-wide RNAi screens, where its knockdown led to decreased viral replication [10, 11]. In the present study, using a combination of mass spectrometry-based proteomics data, mutagenesis and S-palmitoylation assays, we identified four cysteine residues in RNAseK,Cys6, Cys7, Cys14, and Cys85, as sites of S-palmitoylation (Fig. 1). The remaining cysteine, Cys69, was not found to be modified, which is consistent with its localisation within a transmembrane domain, likely rendering it inaccessible to the enzymes responsible for S-palmitoylation [33]. We showed that S-palmitoylation of RNAseK is required for efficient ZIKV replication. Cells lacking RNAseK or expressing a S-palmitoylation-deficient mutant exhibited significantly reduced ZIKV replication as measured by flow cytometry, RT-qPCR of viral genomes, and TCID50 assays. In contrast, reconstitution with wild-type RNAseK restored ZIKV infection to levels comparable to parental control cells (Fig. 2). S-palmitoylation can alter the physicochemical properties of target proteins, often increasing their membrane affinity and disturbing their subcellular localisation [1, 9]. However, our colocalisation analysis using six different organelle markers to assess RNAseK localisation across six membrane-bound compartments (plasma membrane, ER, Golgi apparatus, early endosomes, late endosomes, and lysosomes) showed no significant differences in localisation between RNAseK-FLAG-WT and ΔPalm in any compartment (Fig. 3). These results suggest that the subcellular localisation of RNAseK is not affected by its S-palmitoylation. However, our results revealed that S-palmitoylation of RNAseK enhances its intracellular stability and protects it from proteasomal degradation (Fig. 4). Using a cycloheximide chase assay, we demonstrated that the palmitoylation-deficient RNAseK mutant (ΔPalm) exhibited significantly reduced stability compared to the wild-type protein (Fig. 4). Proteasome inhibition rescued expression of this mutant, indicating that non-palmitoylated RNAseK is targeted for proteasomal degradation (Fig. 4). It is important to note that the cells used in the experiment shown in Figs. 3 and 4A were transiently transfected human cells with pcDNA plasmids encoding RNAseK-FLAG constructs. Consequently, the expression of the different RNAseK-FLAG variants was driven by a strong viral promoter (CMV promoter). This resulted in high expression levels of both RNAseK-FLAG-WT and its less stable variant RNAseK-FLAG-ΔPalm. Indeed, the expression of the RNAseK variants was so robust under this promoter that even the less stable variant could accumulate and be detected by Western blot. In contrast, in the experiments shown in Fig. 4B, the cells were transduced with viral vectors to achieve stable expression of the RNAseK-FLAG variants closer to the native levels. In these cells, the incorporated constructs were not under the control of a strong viral promoter, leading to lower expression levels. At these lower levels, the less stable RNAseK-FLAG-ΔPalm protein did not accumulate to a detectable level by Western blot, as it was degraded by the proteasome. However, it became detectable when we inhibited the proteasomal degradation with the addition of MG132 compound (Fig. 4B). These findings are consistent with studies in other systems showing that S-palmitoylation can shield proteins from ubiquitination and degradation by anchoring them to membranes [34, 35]. The precise mechanism by which RNAseK and its S-palmitoylation contribute to viral replication remains unclear. RNAseK is a subunit of the v-ATPase complex, a proton pump essential for endosomal acidification [13]. Proteomics analyses indicated that loss of RNAseK does not affect the expression of other v-ATPase subunits [12]. Consistently, our observations suggested that neither RNAseK silencing nor expression of the S-palmitoylation-deficient mutant altered the levels of other v-ATPase subunits (Fig. 4). Interestingly, other v-ATPase subunits, including V0a1 [19], are S-palmitoylated, which raises the possibility that multiple lipidation events cooperatively regulate the function or membrane targeting of the complex. Given RNAseK’s role as a v-ATPase subunit, we investigated whether its S-palmitoylation affects lysosomal acidification. Previous studies have reported conflicting findings, with some suggesting that RNAseK depletion does not alter endo-lysosomal acidification, whereas others have reported defects in lysosomal acidification [12, 18]. Using a ratiometric lysosomal pH reporter, we found that loss of RNAseK S-palmitoylation increased lysosomal pH, indicative of impaired acidification (Fig. 5). A similar increase in lysosomal pH was observed upon RNAseK silencing, suggesting that both gene knockdown and loss of S-palmitoylation impair lysosomal function, which may explain their shared inhibitory effect on ZIKV replication, an acid-dependent process. Given that endosomal acidification is a key trigger for viral membrane fusion in flaviviruses, these observations raise the possibility that RNAseK may influence ZIKV entry at the level of membrane fusion. However, our study did not directly assess viral membrane fusion. Direct evaluation of fusion events using dedicated assays will be required to address this possibility in future studies. In addition, given the discrepancies in the literature on the role of RNAseK on lysosomal acidification and the uncertainty regarding the specific step of viral entry regulated by RNAseK, further studies are needed to clarify its precise role. Notably, RNAseK may also facilitate viral entry via mechanisms beyond endosomal acidification [10, 11, 36], as it has been implicated in the early stages of viral entry of diverse acid-dependent viruses, including flaviviruses such as Dengue and West Nile virus, as well as unrelated viruses like Influenza A, Rhinovirus and Rift Valley Fever virus [10, 11, 36]. This suggests that S-palmitoylation of RNAseK may also contribute to additional steps of ZIKV entry, complementary to endosomal acidification. Given the reversible nature of S-palmitoylation, this modification may enable rapid signal-dependent control of RNAseK availability during different stages of viral replication, although this possibility remains to be tested experimentally. Interestingly, total RNAseK protein levels decreased during ZIKV infection, while the fraction of S-palmitoylated RNAseK increased (Fig. 6). The reduction in total RNAseK levels may result from host translational shutoff (Figure S7B), although enhanced protein degradation induced by ZIKV could also contribute. In parallel, the relative enrichment of S-palmitoylated RNAseK among the residual protein pool indicates that this lipid modification may confer a selective advantage, likely by promoting RNAseK stability during infection. In conclusion, this study provides evidence that S-palmitoylation of RNAseK is a crucial post-translational modification that promotes RNAseK protein stability and supports ZIKV infection. Given that the mechanisms of viral entry and endo-lysosomal trafficking are conserved among flaviviruses, it is plausible that RNAseK S-palmitoylation may similarly affect the infection by other members of this viral family. However, as this study was performed using a single ZIKV strain, future work will be required to determine whether this phenotype is conserved across multiple ZIKV strains and clinical isolates, as well as across related flaviviruses. Our findings not only improve our understanding of host factors exploited by flaviviruses, but also highlight the broader importance of protein lipidation in virus-host interactions. The requirement of RNAseK S-palmitoylation for RNAseK stability and its association with viral replication mechanisms highlights this lipid modification as an interesting area for further investigations . Removing this lipid modification may affect RNAseK stability and its in ZIKV infection, thereby influencing infection efficiency. Small-molecule inhibitors of DHHC palmitoyltransferases, such as cyanomyracrylamide, have demonstrated the ability to modulate host S-palmitoylation pathways in vitro [37]. However, these inhibitors are not selective forindividual DHHCs, thus translating these findings into antiviral therapies remains challenging, as S-palmitoylation is a reversible and ubiquitous modification that regulates numerous essential cellular proteins and pathways unrelated to infection. Broad inhibition could therefore lead to off-target effects and cytotoxicity. Future efforts may focus on developing selective strategies to remove RNAseK S-palmitoylation, using induced proximity to a depalmitoylation enzyme, as recently demonstrated by Kuo et al. [38]. This approach would minimise global perturbations of S-palmitoylation networks while leveraging a potential regulatory node in viral infection to achieve broader antiviral potential. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We thank Dr. Mathieu Metifiot for his assistance in setting up the flow cytometry experiments. We acknowledge the Bordeaux Imaging Center, a service unit of CNRS, INSERM, and the University of Bordeaux, and a member of the national infrastructure France BioImaging, supported by the French National Research Agency (ANR-24-INBS-0005, FBI BIOGEN), for access to imaging facilities.We also thank Magali Mondin, Prof. Anthony Bouter and Dr. Anne Royou for their support with microscopy experiments. Author contributions S. L.: Conceptualisation, Investigation, Writing- Original draft preparation, Writing- Reviewing and Editing. P. P. and ML. A.: Methodology, Writing- Reviewing and Editing. L. F.: Investigation and reviewing. E. T.: Funding acquisition, Conceptualisation, Writing- Original draft preparation, Writing- Reviewing and Editing. All authors reviewed the manuscript. Funding This work was supported by research grants from the Agence Nationale de la Recherche (ANR-20-CE44-0015), the Conseil Régional de Nouvelle-Aquitaine (AAPR2020-2019-8034510) and an Idex Junior chair to E.T (OPE 2019 − 0436). Data availability The data presented in this study are available within the article or supplementary material. However, Figure S1 is derived from proteomics analyses conducted in one of our previously published manuscripts [20]. The data was deposited with the ProteomeXchange Consortium via the PRIDE partner repository, with the dataset identifier PXD008399. Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors have read and agreed to this submitted version of our manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data presented in this study are available within the article or supplementary material. However, Figure S1 is derived from proteomics analyses conducted in one of our previously published manuscripts [20]. The data was deposited with the ProteomeXchange Consortium via the PRIDE partner repository, with the dataset identifier PXD008399.